Serologicals Units and Cellumen to Develop, Sell Cytotoxicity Profiling Panel, Services, to Pharma | GenomeWeb

Two divisions of Serologicals and Pittsburgh-based biotech Cellumen plan to co-develop and sell a cytotoxicity profiling panel and services for use in pharmaceutical drug discovery, the firms said this week.

For reagent provider Serologicals, the partnership marks the biggest step it has taken to date in the direction of cell-based assays for drug discovery; specifically, it expects the deal to help it gain a foothold in the high-content cellular-assay market, an area in which it has limited experience.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.